| Drug General Information |
| Drug ID |
D05QTJ
|
| Former ID |
DNC000423
|
| Drug Name |
Chloroethylclonidine
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C13H17Cl3N4
|
| Canonical SMILES |
CN(CCCl)CC1=CC(=C(C(=C1)Cl)NC2=NCCN2)Cl
|
| InChI |
1S/C13H17Cl3N4/c1-20(5-2-14)8-9-6-10(15)12(11(16)7-9)19-13-17-3-4-18-13/h6-7H,2-5,8H2,1H3,(H2,17,18,19)
|
| InChIKey |
XFDVJGKSQRUEEM-UHFFFAOYSA-N
|
| CAS Number |
CAS 98086-36-3
|
| PubChem Compound ID |
|
| PubChem Substance ID |
10233703, 11110807, 15471003, 26755658, 44434528, 47285790, 47350430, 47954381, 50065430, 50110970, 51618293, 57337944, 85209019, 90341347, 92098494, 103100301, 103340708, 104373340, 117472294, 124749532, 124879335, 124879336, 129680080, 134339851, 135062207, 135089706, 162755894, 179235756, 198940830, 230066265, 241137222
|
| Target and Pathway |
| Target(s) |
Alpha-2A adrenergic receptor |
Target Info |
Agonist |
[1]
|
|---|
| Alpha-2C adrenergic receptor |
Target Info |
Agonist |
[1]
|
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interactionhsa04022:cGMP-PKG signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
PANTHER Pathway
|
Alpha adrenergic receptor signaling pathwayP00002:Alpha adrenergic receptor signaling pathway
|
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Reactome
|
Adrenoceptors
|
|
Adrenaline signalling through Alpha-2 adrenergic receptor
|
|
Adrenaline,noradrenaline inhibits insulin secretion
|
|
G alpha (i) signalling events
|
|
G alpha (z) signalling events
|
|
Surfactant metabolismR-HSA-390696:Adrenoceptors
|
|
Surfactant metabolism
|
|
WikiPathways
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Platelet Aggregation (Plug Formation)
|
|
Integration of energy metabolism
|
|
GPCR ligand binding
|
|
GPCR downstream signalingWP58:Monoamine GPCRs
|
|
GPCR downstream signaling
|
| References |
| REF 1 | Selective irreversible binding of chloroethylclonidine at alpha 1- and alpha 2-adrenoceptor subtypes. Mol Pharmacol. 1993 Dec;44(6):1165-70. |
|---|
